Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + chidamide + azacitidine + decitabine + mitoxantrone + cytarabine + granulocyte colony-stimulating factor
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Xiamen University
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
This sequential combination therapy regimen is being evaluated for the treatment of elderly patients with untreated acute myeloid leukemia (AML). The regimen consists of an induction phase using the VCA combination (Venetoclax, Chidamide, and Azacitidine) followed by a consolidation or subsequent phase using the D-MAG regimen (Decitabine plus Mitoxantrone, Cytarabine, and G-CSF). Venetoclax targets BCL-2 to induce apoptosis, Chidamide is an HDAC inhibitor that modulates gene expression, and Azacitidine and Decitabine are hypomethylating agents that reverse epigenetic silencing. The MAG component includes Mitoxantrone (a topoisomerase II inhibitor), Cytarabine (an antimetabolite), and G-CSF (used to prime leukemic blasts or support myeloid recovery). This multi-targeted approach aims to overcome resistance and improve response rates in a high-risk elderly population.
- Other names
- Venetoclax + Chidamide + Azacitidine followed by Decitabine + Mitoxantrone + Cytarabine + G-CSFVeneclax + Chidaniline + Azacitidine + Decitabine + MAG
02
Targets
BCL-2 (BCL-2 family)TOP2A (DNA topoisomerase II)DNMT1 (DNA (cytosine-5)-methyltransferase 1)CSF3R (Granulocyte colony-stimulating factor receptor)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)DNA polymerase family
Beyond the preview
Go deeper on venetoclax + chidamide + azacitidine + decitabine + mitoxantrone + cytarabine + granulocyte colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + chidamide + azacitidine + decitabine + mitoxantrone + cytarabine + granulocyte colony-stimulating factor.